Posted on 13/05/2009 in Pharmaceutical Company Financials Lundbeck has announced 52 per cent of its total revenue for the first quarter of 2009 was from European business.
The rise was driven by the treatments Azilect, Ebixa and Cipralex. Revenues for these products grew by 47, 16 and 13 per cent respectively.
At constant exchange rates, revenue from European markets increased by 12 per cent, which amounted to DKK 1,675 million (201.67 million pounds).
President and chief executive officer of the company Ulf Wiinberg remarked the firm had delivered on the strategic intent of becoming one of the biggest pharmaceutical companies in the world during the first three months of the year due to its acquisition of Ovation.
He said: "We are also pleased with the revenue performance delivering double digit growth in the quarter, where significant growth for our key products and principal markets has been maintained."
Last month, the Food and Drug Administration's Psychopharmacology Drug Advisory Committee declared Lundbeck's Serdolect (sertindole) was effective to treat patients with schizophrenia.
Head of drug development at the company Anders Gersel Pedersen commented the firm would continue to work with the regulatory body on the new drug application for the medication.Other news stories from 13/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
